Menu

Georges GAUDRIAULT

MONTPELLIER

Electionseuropéennes 2024

RETROUVEZ GRATUITEMENTLe résultat des européennes à Montpellier ainsi que le résultat des européennes dans l'Hérault.

En résumé

Mes compétences :
Drug Delivery
Manage the scientific and technological operations
Drug Discovery
Technical Support for BD team
Intellectual property

Entreprises

  • MedinCell SA - Chief Scientific Officer

    2007 - 2016 Medincell is a private drug delivery company committed to the creation and development of long acting parenteral formulations. The corporation, founded in 2002, assists Human and Animal Health companies with BEPO™, its advanced polymeric drug delivery system. BEPO™ drastically improves action durations of small molecules, peptides and proteins after subcutaneous administration. The technology thus allows greater patient compliance and convenience thanks to advantageous pharmacokinetic profiles.
    My function was to head the scientific research operations. I was evaluating and setting scientific priorities as well as managing all intellectual property activities from patents filling to prosecution. I was supporting scientific discussion with client during key business development activities. As part of the executive team, I was participating in all the strategic decisions implicating scientific activities.

  • ObeTherapy Biotechnology SAS - Scientific Director

    2002 - 2007 ObeTherapy is a french start-up biotech company dedicated to the discovery of new targets and the development of new drugs for obesity, hypercholesterolemia and type II diabetes based on lean and/or starvation phenotype. During these five years, I was managing the discovery activities (target validation, HTS screening, and medicinal chemistry)

  • Institut Curie - Research Scientist

    PARIS 5 1999 - 2002 INSERM U528 «Signal transduction and Oncogenesis'',
    Inside the "Oncogenesis and signal transduction" group, I managed a small team focusing on cAMP-GEFII function in cAMP regulation of oncogenesis.

  • Clayton Foundation for Peptide Biology - Research Scientist

    1996 - 1999 Clayton Foundation for Peptide Biology, Salk Institute,
    I initially worked on molecular biology of CRF receptors, one of the main regulators of stress. We discovered a new component of the signaling pathway of these receptors, the cAMP-GEFII. This protein bridge cAMP signaling pathway and some members of the small G-protein family

Formations

Réseau

Pas de contact professionnel

Annuaire des membres :